Home » 제품 » Ready-to-Use NGS Panel » Somatic Cancer » CancerScreen CDx Panels
CancerScreen CDx Panels
Highly optimized somatic cancer NGS panel for Companion Diagnostics
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Revolutionary Bioinformatics solution providing fast and
accurate, client-specific analysis services.
Trust CAS with your BI analysis !
Highly optimized library preparation kit to be used with all Celemics ready-to-use or customized panels. Experience the incomparable efficiency and performance for NGS library preparation
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
Celemics has developed NGS ctDNA-based kits for colon, breast, and lung cancer assays. We have integrated our market-leading proprietary technologies and thoroughly validated and optimized as ready-to-use panels for clinical diagnostics.
Celemics offers end-to-end NGS-based detection and discovery solutions for Biopharma, CRO, and Drug discovery research fields.
In order to overcome the limitations of analyzing clinical diseases with conventional whole exome sequencing, Celemics introduces NGS-based clinical diagnostic solution for efficient detection of disease-causing variants for inherited diseases.
Celemics offers flexible choice of assessing extensive target regions associated with Pharmacogenomics for client-specific drug prescription and drug metabolism.
Celemics’ virus panels are designed to detect and identify disease-causing viruses. With our exclusive technologies, we provide efficient and accurate detection of targeted virus trains as well as procurement of credible data for whole viral genome sequencing.
To fulfill the expectations and growing needs for sequencing animals and plants, Celemics offers range of ready-to-use applicable to agrigenomics field as well as an option for developing customized NGS panel to specifically fit individual research purposes.
With Celemics’ proprietary technologies for assay development and optimization, we offer complete and robust NGS solutions for transcriptome, fusion, and isoform analyses for various sample types and conditions.
Celemics provides comprehensive solution for DNA methylation sequencing with proprietary probes specifically designed for methyl-seq, enabling accurate detection of methylation sites.
Complete solution with flexible panel design for characterization and differentiation of a myriad of microbial species.
Accurate and efficient analysis of IGH population that can detect MRD as low as 10-6 with optimized primers that can minimize sequencing loss and PCR duplications.
Celemics introduces revolutionary BI solution aiming to provide client-specific service. We provide fast, accurate, and sophisticated analyses of your NGS data accompanied by our proprietary bioinformatics pipeline.
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Utilizing NGS-based target enrichment methods for higher genotyping efficiency and accuracy. Providing cost-effective and optimized experiment compared to conventional methods, such as GBS, PCR and microarray in plant and animal research
View Detail >Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >In-silico designed and wet-lab validated exclusive probes to ensure state-of-the-art capture performance
View Detail >Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >Let’s change the NGS market together – our global presence and partners world-wide
View Detail >Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Highly optimized somatic cancer NGS panel for Companion Diagnostics
CancerScreen CDx 패널은 Somatic Cancer와 연관 있는 유전자의 유전변이를 정확하게 분석하기 위해 높은 특이도와 민감도를 갖도록 개발된 패널로 비용 효율적인 분석이 가능합니다. 본 패널은 특히 TERT Promoter 영역과 같이 치료를 위한 약물의 효과에 영향을 미치는 것으로 알려진 유전자들에 집중한 패널로 치료제 효과 검증 등이 필요한 경우에 보다 유용한 정보를 얻을 수 있습니다.
분석이 필요한 유전자가 패널에 없는 경우 Gene Add-on 서비스를 통해 추가할 수 있어 더욱 유용하게 사용할 수 있습니다.
셀레믹스에서는 BI 분석 서비스를 제공하고 있습니다. 고객이 원하는 결과의 수준에 따라 1차 (Primary), 2차 (Secondary), 3차 (Tertiary)의 세분화된 다른 분석 결과를 제공하고 있습니다. BI에 익숙하지 않은 고객들도 별도의 세팅 없이 유전 변이 분석 결과를 얻을 수 있습니다
패널에 포함된 각 유전자의 Coding Exon뿐만 아니라 FDA 승인 치료 약물의 효과에 영향을 주는 모든 주요 유전 변이를 분석할 수 있습니다. SNV, InDel, Large InDel, CNV, Gene Rearrangements를 포함해 MSI, TMB까지 모든 종류의 유전 변이를 한 번의 검사로 분석할 수 있습니다.
CancerScreen CDx 패널은 매우 높은 시퀀싱 Depth를 바탕으로 암종에 대한 약물 치료 효과에 중요하다고 알려진 유전 변이들을 정확히 검출할 수 있습니다. 독자적인 프로브 디자인 기술을 바탕으로 GC-rich 영역이나 Homologous 영역에 발생하는 유전 변이뿐만 아니라 FFPE, ctDNA와 같은 손상되거나 미량인 샘플에 대해서도 최상의 민감도와 특이도로 중요한 유전변이들을 놓치지 않고 분석할 수 있습니다.
유전변이의 병원성, 약물 연관성을 비롯해 타겟 유전자의 기능 정보 등 세분화된 분석 파이프라인을 갖추고 있어 고객이 원하는 결과의 수준에 맞춰 분석 서비스를 진행해 드립니다.
셀레믹스는 시퀀싱 플랫폼 이외의 다른 장비를 필요로 하지 않는 프로토콜을 제공합니다. 독자적인 시약 개발 기술을 통해 기존 Dry, QC에 필요한 장비를 효소와 마그네틱 비드로 대체할 수 있도록 준비했습니다. 또한 기존 20 시간 이상 걸리던 실험 시간을 8 시간 이내로 끝낼 수 있도록 프로토콜을 최적화해 하루 안에 시퀀싱을 수행할 수 있습니다.
Conventional
workflow
» 20 hours
Library Prep
Target Capture
Same-day
workflow
» 5-8 hours
Library Prep
Target Capture
Product Name | CancerScreen CDx DNA Kit | CancerScreen CDx RNA Kit | CancerScreen CDx HRD Kit |
---|---|---|---|
Gene count | 22 | 9 | 15 |
Target size | 73.4 kb | 32.1 kb | 69.4 kb |
Mutation type | SNV, Indel, CNV, Rearrangement | ||
Covered region | Whole CDS, Rearrangement | ||
Sample Type | FFPE, Fresh tissue, etc. | ||
Platform | All sequencers from Illumina and Thermo Fisher | ||
Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF
② Secondary Analysis: CNV, Large InDel, TMB & MSI ③ Tertiary Analysis: Clinical interpretation Visualization Curation (Heatmap, CNV visualization, Statistical analysis, etc.) |
DNA Panel | ALK | BRAF | BRCA1 | BRCA2 | EGFR | ERBB2 |
---|---|---|---|---|---|---|
EZH2 | FGFR3 | FLT3 | IDH2 | IDH2 | KIT | |
KRAS | MET | MYC | MYCN | NF1 | NRAS | |
PDGFRA | PDGFRB | PIK3CA | TP53 |
RNA Panel | ABL1 | ALK | FGFR2 | FGFR3 | NTRK1 | NTRK2 |
---|---|---|---|---|---|---|
NTRK3 | RET | ROS1 |
HRD Panel | ARID1A | ATM | ATRX | BAP1 | BLM | BRCA1 |
---|---|---|---|---|---|---|
BRCA2 | BRIP1 | CHEK2 | FANCC | MRE11 | NBN | |
PALB2 | RAD50 | WRN |
암종과 연관 있는 것으로 알려진 유전자의 염기서열을 포괄적으로 분석하기 위한 패널. Immuno-oncology 마커를 비롯해 Gene Rearrangement 등 다양한 유전 변이를 분석하기 위한 패널
암종과 연관 있는 것으로 알려진 유전자의 염기서열을 포괄적으로 분석하기 위한 패널. Immuno-oncology 마커를 비롯해 Gene Rearrangement 등 다양한 유전 변이를 분석하기 위한 패널
유전성 암과 연관 있는 것으로 보고된 30여 개 유전자의 염기서열 분석을 위한 패널
FDA 승인된 약물과 연관 있는 것으로 알려진 유전변이 검출을 위한 패널로 약물과 연관성이 높은 주요 유전자를 폭넓게 커버하는 패널
셀레믹스에서 제공하는 BI 분석 서비스로 다양한 수준의 분석 결과 제공 가능
Technical Resources
Flyer_CancerScreen CDx Panel
Product Overview] Celemics Target Enrichment Panel Overview
[Catalogue] Celemics Products & Service Catalogue_All Products & Service
Safety Data Sheets
MSDS_CancerScreen CDx Panels_Illumina_Enzymeplus
MSDS_CancerScreen CDx Panels_Illumina
MSDS_CancerScreen CDx Panels_Thermo Fisher
MSDS_CancerScreen CDx Panels_MGI_EnzymePlus
MSDS_CancerScreen CDx Panels_MGI
Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.
10.2217/epi-2021-0477
So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.
DOI 10.4111/icu.20220044
Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.
DOI 10.1038/s41598-022-05931-3
Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.
DOI 10.1186/s12920-022-01191-2